-+ 0.00%
-+ 0.00%
-+ 0.00%

Elicera Therapeutics completes Phase I CARMA trial of ELC-301, posts 67% complete metabolic response rate

PUBT·10/12/2026 11:07:04
Elicera Therapeutics completes Phase I CARMA trial of ELC-301, posts 67% complete metabolic response rate
  • Elicera Therapeutics reported completed dose-escalation in the CARMA Phase I/IIa trial of ELC-301 in relapsed or refractory B-cell lymphoma.
  • Results have already been presented, showing most patients responded, with many reaching no detectable active disease at best response.
  • Responses appeared durable in several patients, supporting continued development despite prior treatment failures in the enrolled population.
  • Safety supported further testing, with no dose-limiting toxicities reported across the evaluated dose cohorts.
  • Recruitment is expected to start in Q4 2026 for the Phase IIa expansion, which will further assess dosing and early efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 202610120705BITN____UKPR__EN_20261012-BIT-2244-0) on October 12, 2026, and is solely responsible for the information contained therein.